**Billington 2019** Billington S, Shoner S, Lee S, Clark-Snustad K, Pennington M, Lewis D, Muzi M, Rene S,Lee J, Nguyen TB, Kumar V, Ishida K, Chen L, Chu X, Lai Y, Salphati L, Hop CECA, Xiao G, Liao M, Unadkat JD (2019) Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A. *Clinical pharmacology and therapeutics* *106*(5):1056–1066 

**Birmingham 2015** Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ (2015) Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? *European journal of clinical pharmacology* *71*(3):341–55

**Cooper 2002** Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2002) The effect of fluconazole on the pharmacokinetics of rosuvastatin. *European journal of clinical pharmacology* *58*(8):527–31

**Cooper 2003a** Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003) Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. *British journal of clinical pharmacology* *55*(1):94–9

**Cooper 2003b** Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV (2003) Effect of itraconazole on the pharmacokinetics of rosuvastatin. *Clinical pharmacology and therapeutics* *73*(4):322–9

**Cooper 2003c** Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW (2003) The effect of erythromycin on the pharmacokinetics of rosuvastatin. *European journal of clinical pharmacology* *59*(1):51–6

**Coss 2016** Coss CC, Jones A, Dalton JT (2016) Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. *Investigational new drugs* *34*(4):458–67

**Csonka 2019** Csonka D, Bruderer S, Schultz A, Soergel M, Stepanova R, Sabattini G, Perez-Ruixo JJ (2019) Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. *Clinical drug investigation* *39*(12):1223–1232

**Edwards 2017** Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L (2017) Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. *Advances in therapy* *34*(9):2120–2138

**FDA 2003** US Food and Drug Administration (FDA) (2003) Approval Package for Application Number 21-366 (Crestor), *Clinical Pharmacology and Biopharmaceutics Review*

**FDA 2018** US Food and Drug Administration (FDA) (2018) Approval Package for NDA 210450 (Orilissa),*Multi-Disciplinary Review and Evaluation*

**Gidal 2017** Gidal BE, Mintzer S, Schwab M, Schutz R, Kharidia J, Blum D, Grinnell T, Sunkaraneni S (2017) Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. *Epilepsy research* 135:64–70

**Goard 2010** Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ (2010) Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. *International journal of cancer* *127*(12):2936–48

**Gosai 2008** Gosai P, Liu J, Doyle RT, Johnson J, Carter R, Sica D, McKenney JM (2008) Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. *Expert opinion on pharmacotherapy* *9*(17):2947–53

**Hanke 2018** Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T (2018) PBPK models for CYP3A4 and P-gp DDI prediction: A modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin. CPT: Pharmacometrics & Systems Pharmacology 7(10):647–659

**Huguet 2016** Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J (2016) No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects. *European journal of clinical pharmacology* *72*(8):925–31

**Jones 2012** Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. *Drug metabolism and disposition: the biological fate of chemicals* *40*(5):1007–17

**Jones 2020** Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW (2020) Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI. *Clinical pharmacology and therapeutics* *107*(1):269–277

**Kitamura 2008** Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug metabolism and disposition: the biological fate of chemicals* *36*(10):2014–23

**Kolesnikov 2015** Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N, Brandizi M, Burdett T, Megy K, Pilicheva E, Rustici G, Tikhonov A, Parkinson H, Petryszak R, Sarkans U, Brazma A (2015) ArrayExpress update—simplifying data submissions. *Nucleic Acids Research* *43*(D1):D1113–D1116

**Kosoglou 2004** Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL (2004) Pharmacodynamic interaction between ezetimibe and rosuvastatin. *Current medical research and opinion* *20*(8):1185–95

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. (2016). Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacometrics Syst Pharmacol*. Oct;5(10), 516-531.

**Lee 2005** Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D (2005) Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clinical pharmacology and therapeutics* *78*(4):330–41

**Lee 2018** Lee J, Rhee SJ, Lee S, Yu KS (2018) Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians. *Drug design, development and therapy* 12:787–794

**Martin 2002a** Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ (2002) No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. *Journal of clinical pharmacology* *42*(10):1116–21

**Martin 2002b** Martin PD, Mitchell PD, Schneck DW (2002) Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. *British journal of clinical pharmacology* *54*(5):472–7

**Martin 2003b** Martin PD, Warwick MJ, Dane AL, Cantarini MV (2003) A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.*Clinical therapeutics* *25*(8):2215–24

**Martin 2003c** Martin PD, Warwick MJ, Dane AL, Brindley C, Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. *Clinical therapeutics* *25*(10):2553–63

**Martin 2003d** Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E (2003) Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. *Clinical therapeutics* *25*(11):2822–35

**Martin 2016** Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, Oliver S, Holmes V, Severin P, Elsby R (2016) Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies. *Drugs in R&D* *16*(1):93–107

**McTaggart 2001** McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. *The American journal of cardiology* *87*(5A):28B–32B

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. (2012). Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. *Drug Metab Dispos*. May;40(5), 892-901.

**Nishimura 2003** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi.* May;123(5), 369-75.

**Prasad 2014** Prasad B, Evers R, Gupta A, Hop CECA, Salphati L, Shukla S, Ambudkar SV, Unadkat JD (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and PGlycoprotein (ABCB1) protein expression: Quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metabolism and Disposition 42(1):78–88

**Prueksaritanont 2014**  Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA (2014) Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. *British journal of clinical pharmacology* *78*(3):587–98

**Prueksaritanont 2017** Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA (2017) Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. *Clinical pharmacology and therapeutics* *101*(4):519–530

**Riccardi 2019** Riccardi KA, Tess DA, Lin J, Patel R, Ryu S, Atkinson K, Di L, Li R (2019) A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes. *Drug metabolism and disposition: the biological fate of chemicals* *47*(5):484–492

**Schneck 2004** Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CDA, Windass AS, Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clinical pharmacology and therapeutics* *75*(5):455–63

**Seo 2019** Seo KS, Han HK (2019) Multilayer-Coated Tablet of Clopidogrel and Rosuvastatin: Preparation and In Vitro/In vivo Characterization. *Pharmaceutics* *11*(7)

**Stopfer 2016** Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Zimdahl-Gelling H, Gansser D, Wein M, Ebner T, Müller F (2016) Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. *Clinical pharmacology and therapeutics* *100*(3):259–67.

**Stopfer 2018a** Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Jungnik A, Gansser D, Ebner T, Müller F (2018) Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. *European journal of drug metabolism and pharmacokinetics* *43*(1):69–80

**Stopfer 2018b** Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D, Ishiguro N, Taub ME, Sharma A, Ebner T, Müller F (2018) Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. *British journal of clinical pharmacology* *84*(9):1941–1949

**TGA 2011** Australian Therapeutic Goods Administration (TGA) (2011) Crestor - Product Information

**Wiebe 2020** Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, Ebner T, Mikus G, Fromm MF, Müller F, Stopfer P (2020) Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. *Clinical pharmacokinetics*

**Willis 2020** Willis BA, Andersen SW, Ayan-Oshodi M, James DE, Liffick E, Hillgren K, Guo Y, Monk SA (2020) Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat. *Journal of clinical pharmacology* *60*(1):107–116

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn.* 34(3), 401-431.

**Windass 2007** Windass AS, Lowes S, Wang Y, Brown CDA (2007) The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. *The Journal of pharmacology and experimental therapeutics* *322*(3):1221–7

**Wishart 2006** Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Research 34*(Supplement 1):D668–D672

**Wu 2017** Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ (2017) Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. *Journal of pharmaceutical sciences* *106*(9):2751–2757.
